Evidence map›Paper›PMID 12020338›Full record

Trial reportJAMA2002

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group

4 registry-linked trialsOpen access · bronzeAbstract readClinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JAMA, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 309 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
309citing papers in PubMed, 12 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02879409 naactive not recruitingstarted 2016, after this paper: background citation

Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?

Ran2016Enrolled150Registered outcomes4Posted comparisons0ConditionsDiabetes Mellitus Type 2Armsdapagliflozin, Gliclazide, human insulin, liraglutide, Metformin
PMID 9742977PMID 19092145PMID 9886743PMID 9742976PMID 10938048PMID 14694008PMID 15189396PMID 15921524PMID 16004665PMID 16801566PMID 17490424PMID 18040661other papers from this trial
Open the trial in the graph
NCT00360893 active not recruitingnot on this map

Epidemiology of Diabetes Interventions and Complications (EDIC)

TypeobservationalSponsorGeorge Washington UniversityRan1994 to 2027Enrolled1,441ConditionsType 1 Diabetes Mellitus
NCT02648685 completednot on this mapstarted 2015, after this paper: background citation

The Study to Investigate the Contribution of Basal and Post-prandial Blood Glucose to Overall Glycaemia in Subjects With Normal Glycaemic Metabolism and Type 2 Diabetes

TypeobservationalSponsorWest China HospitalRan2015 to 2019Enrolled337ConditionsDiabetes, Type 2
NCT05477030 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Effect of Automated Insulin Delivery With Advanced Closed-loop on Glucose Outcomes and Early-stage Diabetic Complications

TypeinterventionalSponsorUniversity of MilanRan2022 to 2024Enrolled52ConditionsType 1 DiabetesArmsMedtronic MiniMed 780G with SmartGuard activation, Medtronic MiniMed 780G without SmartGuard activation
3 · Its place in the literature

Who cites it

309 citing papers in PubMed, 12 syntheses or guidelines pooled it, 947 citations in OpenAlex.

  1. Guideline
  2. Blood pressure control for diabetic retinopathy.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Blood pressure control for diabetic retinopathy.The Cochrane database of systematic reviews · 2015
    Pooled it
  11. Pooled it
  12. Guideline
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

249 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group

Funding

EPIDEMIOLOGY OF DIABETES INTERVENTIONS &COMPLICATIONSN01DK062204 · GEORGE WASHINGTON UNIVERSITY · 1996 to 2004
$2.1M
NIDDK NIH HHS N01 DK062204
6 · The paper itself

Abstract

The purpose of this report is to summarize and integrate the findings of the Diabetes Control and Complications Trial (DCCT), a randomized controlled clinical trial, and the succeeding observational follow-up of the DCCT cohort in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, regarding the effects of intensive treatment on the microvascular complications of type 1 diabetes mellitus. The DCCT proved that intensive treatment reduced the risks of retinopathy, nephropathy, and neuropathy by 35% to 90% compared with conventional treatment. The absolute risks of retinopathy and nephropathy were proportional to the mean glycosylated hemoglobin (HbA(1c)) level over the follow-up period preceding each event. Intensive treatment was most effective when begun early, before complications were detectable. These risk reductions, achieved at a median HbA(1c) level difference of 9.1% for conventional treatment vs 7.3% for intensive treatment have been maintained through 7 years of EDIC, even though the difference in mean HbA(1c) levels of the 2 former randomized treatment groups was only 0.4% at 1 year (P<.001) (8.3% in the former conventional treatment group vs 7.9% in the former intensive treatment group), continued to narrow, and became statistically nonsignificant by 5 years (8.1% vs 8.2%, P =.09). The further rate of progression of complications from their levels at the end of the DCCT remains less in the former intensive treatment group. Thus, the benefits of 6.5 years of intensive treatment extend well beyond the period of its most intensive implementation. Intensive treatment should be started as soon as is safely possible after the onset of type 1 diabetes mellitus and maintained thereafter, aiming for a practicable target HbA(1c) level of 7.0% or less.

Indexed as

AdolescentAdultAlbuminuriaDiabetes Mellitus, Type 1Diabetic AngiopathiesDiabetic NephropathiesDiabetic NeuropathiesDiabetic RetinopathyFemaleGlycated HemoglobinHumansMaleRandomized Controlled Trials as TopicGlycated Hemoglobin

Identifiers

PMID12020338
PMCPMC2622728
OpenAlexW2757208104

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.